Obesity pp 1-12 | Cite as

White Adipose Tissue: Beyond Fat Storage

Chapter

Abstract

White adipose tissue is a highly active metabolic and endocrine organ containing adipocytes, connective tissue matrix, nerve tissue, stromovascular and immune cells and secretes many adipokines such as leptin, adiponectin, cytokines, plasminogen activator inhibitor-1, complements components, proteins of the renin-angiotensin system, and resistin, and considered also a major site for metabolism of corticosteroid hormones.

In obesity, increased production of most adipokines having impacts on multiple functions such as appetite and energy balance, insulin sensitivity, angiogenesis, blood pressure, lipid metabolism, all of which are linked with cardiovascular disease. A better understanding of the endocrine function of adipose tissue will likely lead to more rational therapy for these increasingly prevalent disorders. This chapter will provide a brief overview of the metabolic and endocrine functions of adipose tissue.

Keywords

Adipose tissue Adipokines Obesity Metabolic syndrome Insulin resistance Atherosclerosis 
This is a preview of subscription content, log in to check access.

References

  1. 1.
    Giordano A, Smorlesi A, Frontini A, et al. White, brown and pink adipocytes: the extraordinary plasticity of the adipose organ. Eur J Endocrinol. 2014;170:R159–71.PubMedCrossRefGoogle Scholar
  2. 2.
    Frontini A, Cinti S. Distribution and development of brown adipocytes in the murine and human adipose organ. Cell Metab. 2010;11:253–6.PubMedCrossRefGoogle Scholar
  3. 3.
    Cannon B, Nedergaard J. Brown adipose tissue: function and physiological significance. Physiol Rev. 2004;84:277–359.PubMedCrossRefGoogle Scholar
  4. 4.
    Marti A, Berraondo B, Martinez JA. ‘Obese’ protein slims mice. Science. 1995;269:475–6.CrossRefGoogle Scholar
  5. 5.
    Chaldakov GN, Stankulov IS, Hristova M, et al. Adipobiology of disease: adipokines and adipokine-targeted pharmacology. Curr Pharm Des. 2003;9:1023–31.PubMedCrossRefGoogle Scholar
  6. 6.
    Ahima RS, Flier JS. Adipose tissue as an endocrine organ. Trends Endocrinol Metab. 2000;11:327–32.PubMedCrossRefGoogle Scholar
  7. 7.
    Fruhbeck G, Gomez-Ambrosi J, Muruzabal FJ, et al. The adipocyte: a model for integration of endocrine and metabolic signaling in energy metabolism regulation. Am J Physiol Endocrinol Metab. 2001;280:E827–47.PubMedGoogle Scholar
  8. 8.
    Ahima RS, Saper CB, Flier JS, et al. Leptin regulation of neuroendocrine systems. Front Neuroendocrinol. 2000;21:263–307.PubMedCrossRefGoogle Scholar
  9. 9.
    Ahima RS, Kelly J, Elmquist JK, et al. Distinct physiologic and neuronal responses to decreased leptin and mild hyperleptinemia. Endocrinology. 1999;140:4923–31.PubMedGoogle Scholar
  10. 10.
    Flier JS. Clinical review 94: what’s in a name? In search of leptin’s physiologic role. J Clin Endocrinol Metabol. 1998;83:1407–13.Google Scholar
  11. 11.
    Coleman DL. Effects of parabiosis of obese with diabetes and normal mice. Diabetologia. 1973;9:294–8.PubMedCrossRefGoogle Scholar
  12. 12.
    Farooqi IS, Jebb SA, Langmack G, et al. Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N Engl J Med. 1999;341:879–84.PubMedCrossRefGoogle Scholar
  13. 13.
    Clement K, Vaisse C, Lahlou N, et al. A mutation in the human leptin receptor gene causes obesity and pituitary dysfunction. Nature. 1998;392:398–401.PubMedCrossRefGoogle Scholar
  14. 14.
    Bakker AH, Van Dielen FM, Greve JW, et al. Preadipocyte number in omental and subcutaneous adipose tissue of obese individuals. Obes Res. 2004;12:488–98.PubMedCrossRefGoogle Scholar
  15. 15.
    Montez JM, Soukas A, Asilmaz E, et al. Acute leptin deficiency, leptin resistance, and the physiologic response to leptin withdrawal. Proc Natl Acad Sci U S A. 2005;102:2537–42.PubMedCentralPubMedCrossRefGoogle Scholar
  16. 16.
    Wallace AM, McMahon AD, Packard CJ, et al. Plasma leptin and the risk of cardiovascular disease in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation. 2001;104:3052–6.PubMedCrossRefGoogle Scholar
  17. 17.
    Bjorbaek C, Kahn BB. Leptin signaling in the central nervous system and the periphery. Recent Prog Horm Res. 2004;59:305–31.PubMedCrossRefGoogle Scholar
  18. 18.
    Flier JS, Harris M, Hollenberg AN. Leptin, nutrition, and the thyroid: the why, the wherefore, and the wiring. J Clin Invest. 2000;105:859–61.PubMedCentralPubMedCrossRefGoogle Scholar
  19. 19.
    Hileman SM, Pierroz DD, Flier JS. Leptin, nutrition, and reproduction: timing is everything. J Clin Endocrinol Metab. 2000;85:804–7.PubMedCrossRefGoogle Scholar
  20. 20.
    Chan JL, Heist K, DePaoli A, et al. The role of falling leptin levels in the neuroendocrine and metabolic adaptation to short term starvation in healthy men. J Clin Invest. 2003;111:1409–21.PubMedCentralPubMedCrossRefGoogle Scholar
  21. 21.
    Margetic S, Gazzola C, Pegg GG, et al. Leptin: a review of its peripheral actions and interactions. Int J Obes Relat Metab Disord. 2002;26:1407–33.PubMedCrossRefGoogle Scholar
  22. 22.
    Lord GM, Matarese G, Howard JK, et al. Leptin modulates the T-cell immune response and reverses starvation-induced immunosuppression. Nature. 1998;394:897–901.PubMedCrossRefGoogle Scholar
  23. 23.
    Chandran M, Phillips SA, Ciaraldi T, et al. Adiponectin: more than just another fat cell hormone? Diabetes Care. 2003;26:2442–50.PubMedCrossRefGoogle Scholar
  24. 24.
    Fain JN, Madan AK, Hiler ML, et al. Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans. Endocrinology. 2004;145:2273–82.PubMedCrossRefGoogle Scholar
  25. 25.
    Maeda K, Okubo K, Shimomura I, et al. cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). Biochem Biophys Res Commun. 1996;221:286–9.PubMedCrossRefGoogle Scholar
  26. 26.
    Scherer PE, Williams S, Fogliano M, et al. A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem. 1995;270:26746–9.PubMedCrossRefGoogle Scholar
  27. 27.
    Nakano Y, Tobe T, Choi-Miura NH. Isolation and characterization of GBP28, a novel gelatin-binding protein purified from human plasma. J Biochem. 1996;120:803–12.PubMedCrossRefGoogle Scholar
  28. 28.
    Hu E, Liang P, Spiegelman BM. AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem. 1996;271:10697–703.PubMedCrossRefGoogle Scholar
  29. 29.
    Diez JJ, Iglesias P. The role of the novel adipocyte-derived hormone adiponectin in human disease. Eur J Endocrinol. 2003;148:293–300.PubMedCrossRefGoogle Scholar
  30. 30.
    Hotta K, Funahashi T, Bodkin NL, et al. Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys. Diabetes. 2001;50:1126–33.PubMedCrossRefGoogle Scholar
  31. 31.
    Kinlaw WB, Marsh B. Adiponectin and HIV-lipodystrophy: taking HAART. Endocrinology. 2004;145:484–6.PubMedCrossRefGoogle Scholar
  32. 32.
    Ouchi N, Kihara S, Arita Y, et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation. 1999;100:2473–6.PubMedCrossRefGoogle Scholar
  33. 33.
    Tan KC, Xu A, Chow WS, et al. Hypoadiponectinemia is associated with impaired endothelium-dependent vasodilation. J Clin Endocrinol Metabol. 2004;89:765–9.CrossRefGoogle Scholar
  34. 34.
    Yamauchi T, Kamon J, Waki H, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med. 2001;7:941–6.PubMedCrossRefGoogle Scholar
  35. 35.
    Yamauchi T, Kamon J, Waki H, et al. Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis. J Biol Chem. 2003;278:2461–8.PubMedCrossRefGoogle Scholar
  36. 36.
    Yamauchi T, Kamon J, Minokoshi Y, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med. 2002;8:1288–95.PubMedCrossRefGoogle Scholar
  37. 37.
    Bruun JM, Lihn AS, Verdich C, et al. Regulation of adiponectin by adipose tissue-derived cytokines: in vivo and in vitro investigations in humans. Am J Physiol Endocrinol Metab. 2003;285:E527–33.PubMedCrossRefGoogle Scholar
  38. 38.
    Pischon T, Girman CJ, Hotamisligil GS, et al. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA. 2004;291:1730–7.PubMedCrossRefGoogle Scholar
  39. 39.
    Schulze MB, Shai I, Rimm EB, et al. Adiponectin and future coronary heart disease events among men with type 2 diabetes. Diabetes. 2005;54:534–9.PubMedCrossRefGoogle Scholar
  40. 40.
    Lindsay RS, Resnick HE, Zhu J. Adiponectin and coronary heart disease: the Strong Heart Study. Arterioscler Thromb Vasc Biol. 2005;25:15–6.CrossRefGoogle Scholar
  41. 41.
    Spranger J, Kroke A, Mohlig M, et al. Adiponectin and protection against type 2 diabetes mellitus. Lancet. 2003;361:226–8.PubMedCrossRefGoogle Scholar
  42. 42.
    Lindsay RS, Funahashi T, Hanson RL, et al. Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet. 2002;360:57–8.PubMedCrossRefGoogle Scholar
  43. 43.
    Katsuki A, Sumida Y, Murashima S. Serum levels of tumor necrosis factor-alpha are increased in obese patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metabol. 1998;83:859–62.Google Scholar
  44. 44.
    Ruan H, Lodish HF. Insulin resistance in adipose tissue: direct and indirect effects of tumor necrosis factor-α. Cytokine Growth Factor Rev. 2003;14:447–55.PubMedCrossRefGoogle Scholar
  45. 45.
    Hotamisligil GS. Inflammatory pathways and insulin action. Int J Obes Relat Metab Disord. 2003;27 Suppl 3:S53–5.PubMedCrossRefGoogle Scholar
  46. 46.
    Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor- α: direct role in obesity-linked insulin resistance. Science. 1993;259:87–91.PubMedCrossRefGoogle Scholar
  47. 47.
    Ruan H, Miles PD, Ladd CM, et al. Profiling gene transcription in vivo reveals adipose tissue as an immediate target of tumor necrosis factor- α: implications for insulin resistance. Diabetes. 2002;51:3176–88.PubMedCrossRefGoogle Scholar
  48. 48.
    Yudkin JS, Eringa E, Stehouwer CD. ‘Vasocrine’ signalling from perivascular fat: a mechanism linking insulin resistance to vascular disease. Lancet. 2005;365:1817–20.PubMedCrossRefGoogle Scholar
  49. 49.
    Boyle PJ. What are the effects of peroxisome proliferator-activated receptor agonists on adiponectin, tumor necrosis factor-alpha, and other cytokines in insulin resistance? Clin Cardiol. 2004;27:1111–6.CrossRefGoogle Scholar
  50. 50.
    Ridker PM, Rifai N, Pfeffer M, et al. Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. Circulation. 2000;101:2149–53.PubMedCrossRefGoogle Scholar
  51. 51.
    Mohamed-Ali V, Pinkney JK. Adipose tissue as an endocrine and paracrine organ. I J Obes Relat Metab Dis. 1998;22:1145–58.CrossRefGoogle Scholar
  52. 52.
    Mohamed-Ali V, Goodrick S, Rawesh A, et al. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metabol. 1997;82:4196–200.Google Scholar
  53. 53.
    Fried SK, Bunkin DA, Greenberg AS. Omental and subcutaneous adipose tissues of obese subjects release interleukin-6. Depot difference and regulation by glucocorticoid. J Clin Endocrinol Metabol. 1998;83:847–50.Google Scholar
  54. 54.
    Wajchenberg BL. Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr Rev. 2000;21:697–738.PubMedCrossRefGoogle Scholar
  55. 55.
    Fernandez-Real JM, Ricart W. Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocr Rev. 2003;24:278–301.PubMedCrossRefGoogle Scholar
  56. 56.
    Bastard JP, Jardel C, Bruckert E, et al. Elevated levels of interleukin 6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss. J Clin Endocrinol Metabol. 2000;85:3338–42.Google Scholar
  57. 57.
    Tsigos C, Papanicolaou DA, Kyrou I, et al. Dose-dependent effects of recombinant human interleukin-6 on glucose regulation. J Clin Endocrinol Metabol. 1997;82:4167–70.CrossRefGoogle Scholar
  58. 58.
    Senn JJ, Klover PJ, Nowak IA, et al. Suppressor of cytokine signaling-3 (SOCS-3), a potential mediator of interleukin-6-dependent insulin resistance in hepatocytes. J Biol Chem. 2003;278:13740–6.PubMedCrossRefGoogle Scholar
  59. 59.
    Rotter Sopasakis V, Larsson BM, et al. Short-term infusion of interleukin-6 does not induce insulin resistance in vivo or impair insulin signalling in rats. Diabetologia. 2004;47:1879–87.PubMedCrossRefGoogle Scholar
  60. 60.
    De Benedetti F, Alonzi T, Moretta A, et al. Interleukin 6 causes growth impairment in transgenic mice through a decrease in insulin-like growth factor-I. A model for stunted growth in children with chronic inflammation. J Clin Invest. 1997;99:643–50.PubMedCentralPubMedCrossRefGoogle Scholar
  61. 61.
    Wallenius V, Wallenius K, Ahren B, et al. Interleukin-6-deficient mice develop matureonset obesity. Nat Med. 2002;8:75–9.PubMedCrossRefGoogle Scholar
  62. 62.
    Van Harmelen V, Reynisdottir S, Cianflone K, et al. Mechanisms involved in the regulation of free fatty acid release from isolated human fat cells by acylation-stimulating protein and insulin. J Biol Chem. 1999;274:18243–51.PubMedCrossRefGoogle Scholar
  63. 63.
    Cianflone K, Xia Z, Chen LY. Critical review of acylation-stimulating protein physiology in humans and rodents. Biochim Biophys Acta. 2003;1609:127–43.PubMedCrossRefGoogle Scholar
  64. 64.
    Maslowska M, Vu H, Phelis S, et al. Plasma acylation stimulating protein, adipsin and lipids in non-obese and obese populations. Eur J Clin Investig. 1999;29:679–86.CrossRefGoogle Scholar
  65. 65.
    Holcomb IN, Kabakoff RC, Chan B, et al. FIZZ1, a novel cysteine-rich secreted protein associated with pulmonary inflammation, defines a new gene family. EMBO J. 2000;19:4046–55.PubMedCentralPubMedCrossRefGoogle Scholar
  66. 66.
    Steppan CM, Bailey ST, Bhat S, et al. The hormone resistin links obesity to diabetes. Nature. 2001;409:307–12.PubMedCrossRefGoogle Scholar
  67. 67.
    Banerjee RR, Lazar MA. Resistin: molecular history and prognosis. J Mol Med. 2003;81:218–26.PubMedGoogle Scholar
  68. 68.
    Steppan CM, Lazar MA. The current biology of resistin. J Int Med. 2004;255:439–47.CrossRefGoogle Scholar
  69. 69.
    Rajala MW, Obici S, Scherer PE, et al. Adipose-derived resistin and gut-derived resistin-like molecule-beta selectively impair insulin action on glucose production. J Clin Investig. 2003;111:225–30.PubMedCentralPubMedCrossRefGoogle Scholar
  70. 70.
    Ukkola O. Resistin-a mediator of obesity-associated insulin resistance or an innocent bystander? Eur J Endocrinol. 2002;147:571–4.PubMedCrossRefGoogle Scholar
  71. 71.
    Savage DB, Sewter CP, Klenk ES, et al. Resistin/Fizz3 expression in relation to obesity and peroxisome proliferator-activated receptor-action in humans. Diabetes. 2001;50:2199–202.PubMedCrossRefGoogle Scholar
  72. 72.
    Reilly MP, Lehrke M, Wolfe ML, et al. Resistin is an inflammatory marker of atherosclerosis in humans. Circulation. 2005;111:932–9.PubMedCrossRefGoogle Scholar
  73. 73.
    Ghosh S, Singh AK, Aruna B, et al. The genomic organization of mouse resistin reveals major differences from the human resistin: functional implications. Gene. 2003;305:27–34.PubMedCrossRefGoogle Scholar
  74. 74.
    Osawa H, Onuma H, Murakami A, et al. Systematic search for single nucleotide polymorphisms in the resistin gene. The absence of evidence for the association of three identified single nucleotide polymorphisms with Japanese type 2 diabetes. Diabetes. 2002;51:863–6.PubMedCrossRefGoogle Scholar
  75. 75.
    Engert JC, Vohl MC, Williams SM, et al. 5′ Flanking variants of resistin are associated with obesity. Diabetes. 2002;51:1629–34.PubMedCrossRefGoogle Scholar
  76. 76.
    Wang H, Chu WS, Hemphill C, et al. Human resistin gene: molecular scanning and evaluation of association with insulin sensitivity and type 2 diabetes in Caucasians. J Clin Endocrinol Metabol. 2002;87:2520–4.CrossRefGoogle Scholar
  77. 77.
    Alessi MC, Peiretti F, Morange P, et al. Production of plasminogen activator inhibitor by human adipose tissue: possible link between visceral fat accumulation and vascular disease. Diabetes. 1997;46:860–7.PubMedCrossRefGoogle Scholar
  78. 78.
    Bastelica D, Morange P, Berthet B, et al. Stromal cells are the main plasminogen activator inhibitor-1-producing cells in human fat: evidence of differences between visceral and subcutaneous deposits. Arterioscler Thromb Vasc Biol. 2002;22:173–8.PubMedCrossRefGoogle Scholar
  79. 79.
    Mertens I, Van Gaal LF. Obesity, haemostasis and the fibrinolytic system. Obes Rev. 2002;3:85–101.PubMedCrossRefGoogle Scholar
  80. 80.
    Juhan-Vague I, Alessi MC, Mavri A, et al. Plasminogen activator inhibitor-1, inflammation, obesity, insulin resistance and vascular risk. J Thromb Haemost. 2003;1:1575–9.PubMedCrossRefGoogle Scholar
  81. 81.
    Ailhaud G, Fukamizu A, Massiera F, et al. Angiotensinogen, angiotensin II and adipose tissue development. Int J Obes Relat Metab Dis. 2000;24:S33–5.CrossRefGoogle Scholar
  82. 82.
    Engeli S, Schling P, Gorzelniak K, et al. The adipose-tissue renin-angiotensin-aldosterone system: role in the metabolic syndrome? Int J Biochem Cell Biol. 2003;35:807–25.PubMedCrossRefGoogle Scholar
  83. 83.
    Goossens GH, Blaak EE, van Baak MA. Possible involvement of the adipose tissue renin-angiotensin system in the pathophysiology of obesity and obesity-related disorders. Obes Rev. 2003;4:43–55.PubMedCrossRefGoogle Scholar
  84. 84.
    Pollare T, Lithell H, Berne C. A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med. 1989;321:868–73.PubMedCrossRefGoogle Scholar
  85. 85.
    Rubin GL, Zhao Y, Kalus AM, et al. Peroxisome proliferator receptor gamma ligands inhibit estrogen biosynthesis in human breast adipose tissue: possible implication for breast cancer therapy. Cancer Res. 2000;60:1604–8.PubMedGoogle Scholar
  86. 86.
    Seckl JR. 11beta-hydroxysteroid dehydrogenases: changing glucocorticoid action. Curr Opin Pharmacol. 2004;4:597–602.PubMedCrossRefGoogle Scholar
  87. 87.
    Belanger C, Luu-The V, Dupont P, et al. Adipose tissue intracrinology: potential importance of local androgen/estrogen metabolism in the regulation of adiposity. Horm Metab Res. 2002;34:737–45.PubMedCrossRefGoogle Scholar
  88. 88.
    Meseguer A, Puche C, Cabero A. Sex steroid biosynthesis in white adipose tissue. Horm Metab Res. 2002;34:731–6.PubMedCrossRefGoogle Scholar
  89. 89.
    Stulnig TM. WaldhauslW 11 β -Hydroxysteroid dehydrogenase type 1 in obesity and type 2 diabetes. Diabetologia. 2004;47:1–11.PubMedCrossRefGoogle Scholar
  90. 90.
    Seckl JR, Walker BR. Mini review: 11β-hydroxysteroid dehydrogenase type 1-a tissue-specific amplifier of glucocorticoid action. Endocrinology. 2001;142:1371–6.PubMedGoogle Scholar
  91. 91.
    Walker BR, Connacher AA, Lindsay RM, et al. Carbenoxolone increases hepatic insulin sensitivity in man: a novel role for 11- oxosteroid reductase in enhancing glucocorticoid receptor activation. J Clin Endocrinol Metab. 1995;80:3155–9.PubMedGoogle Scholar
  92. 92.
    Xie QW, Kashiwabara Y, Nathan C. Role of transcription factor NF-B/Rel in induction of nitric oxide synthase. J Biol Chem. 1994;269:4705–8.PubMedGoogle Scholar
  93. 93.
    Goto M, Katayama KI, Shirakawa F, et al. Involvement of NF-B p50/p65 heterodimer in activation of the human prointerleukin-1β gene at two sub regions of the upstream enhancer element. Cytokine. 1999;11:16–28.PubMedCrossRefGoogle Scholar
  94. 94.
    O’Rourke L, Gronning LM, Yeaman SJ. Glucose-dependent regulation of cholesterol ester metabolism in macrophages by insulin and leptin. J Biol Chem. 2002;277:42557–62.PubMedCrossRefGoogle Scholar
  95. 95.
    Yudkin JS, Kumari M, Humphries SE. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis. 2000;148:209–14.PubMedCrossRefGoogle Scholar
  96. 96.
    Ridker PM, Rifai N, Rose L, et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002;347:1557–65.PubMedCrossRefGoogle Scholar
  97. 97.
    Fukuhara A, Matsuda M, Nishizawa M. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science. 2005;307:426–30.PubMedCrossRefGoogle Scholar
  98. 98.
    Stentz FB, Umpierrez GE, Cuervo R. Proinflammatory cytokines, markers of cardiovascular risks, oxidative stress, and lipid peroxidation in patients with hyperglycemic crises. Diabetes. 2004;53:2079–86.PubMedCrossRefGoogle Scholar
  99. 99.
    Cai H, Li Z, Dikalov S, et al. NAD (P) H oxidase-derived hydrogen peroxide mediates endothelial nitric oxide production in response to angiotensin II. J Biol Chem. 2002;277:48311–7.PubMedCrossRefGoogle Scholar
  100. 100.
    Widlansky ME, Gokce N, Keaney JF, et al. The clinical implications of endothelial dysfunction. J Am Coll Cardiol. 2003;42:1149–60.PubMedCrossRefGoogle Scholar
  101. 101.
    Kawanami D, Maemura K, Takeda N, et al. Direct reciprocal effects of resistin and adiponectin on vascular endothelial cells: a new insight into adipocytokine–endothelial cell interactions. Biochem Biophys Res Commun. 2004;314:415–9.PubMedCrossRefGoogle Scholar
  102. 102.
    Verma S, Li SH, Wang CH. Resistin promotes endothelial cell activation: further evidence of adipokine–endothelial interaction. Circulation. 2003;108:736–40.PubMedCrossRefGoogle Scholar
  103. 103.
    Jambrik Z, Venneri L, Varga A, et al. Peripheral vascular endothelial function testing for the diagnosis of coronary artery disease. Am Heart J. 2004;148:684–9.PubMedCrossRefGoogle Scholar
  104. 104.
    Calabro P, Samudio I, Willerson JT, et al. Resistin promotes smooth muscle cell proliferation through activation of extracellular signal-regulated kinase 1/2 and phosphatidylinositol 3-kinase pathways. Circulation. 2004;110:3335–40.PubMedCrossRefGoogle Scholar
  105. 105.
    Pinkney JH, Stehouwer CD, Coppack SW, et al. Endothelial dysfunction: cause of the insulin resistance syndrome. Diabetes. 1997;46:S9–13.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  1. 1.Department of Internal MedicineAl Mouwasat HospitalJubailKingdom of Saudi Arabia

Personalised recommendations